It was a pleasure to meet with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) to explore the efficacy and safety findings from the phase 3 study of MV130 for the prevention of COPD exacerbations.
The abstract ‘Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations.’ (Presentation ID 207) was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- What were the aims, design, and clinical outcome measures of the phase 3 study? (0:38)
- What were the efficacy and safety findings from the study? (2:51)
- What are the implications of these findings for patients with COPD? (6:05)
Disclosures: Luis Puente-Maestu has received personally or for his department grants, funds, fees or equipment from GSK, Boheringer, Astra-Zeneca, MSD, Esteve, Chiesi, Menarini, Boston Scientific and air liquide.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
